恆指曾回升近300點 阿里、騰訊及美團升逾2%至4%
恆指過去七連跌累挫950點或5.6%後,今早隨美股及區內股市高開56點或近0.4%,報16,154,升幅曾擴至291點一度高見16,389,現報16,316,回升218點或近1.4%,總成交額344億元。此外,科指及國指均由逾一年低位各回升1.5%及1.3%,曾分別高見3,512及5,522。
藍籌股普遍造好,尤其是藥明生物(02269.HK)今早曾急漲19%一度高見33.4元,現報31元,續升11%。該公司上調今年藥物開發目標及與BioNTech(BNTX.US)就兩款單抗達成研究服務協議。
藥明康德(02359.HK)重越10天及20天線,股價曾升9.3%至80.95元,現報77.9元,續升5.2%。國藥(01099.HK)續升2.7%報20.9元。
內需股以美團(03690.HK)表現最好,最高見76.1元,現報74.8元,續升4.3%。萬洲(00288.HK)升4.3%報5.15元,股價升破20天及10天線。比亞迪(01211.HK)及理想汽車(02015.HK)回升3.1%及2.8%,分別報211元及128.7元。
騰訊(00700.HK)及阿里(09988.HK)股價最高各見289.8元及71.3元,現報287.2元及70.8元,回升2.5%及2.2%。京東(09618.HK)續升1.4%股價曾高見101元。
恆隆地產(00101.HK)、新世界(00017.HK)及九倉置業(01997.HK)股價升近3%至3.5%,報10.62元、11.34元及24.4元。金融股以友邦(01299.HK)、中銀(02388.HK)、港交所(00388.HK)及中國平安(02318.HK)表現較好,股價均升逾1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.